STAT

AI for drug development: Experts break down what’s possible — and what’s just hype

People like to throw around buzzwords like ‘AI’ and ‘big data,’ but in a STAT panel this week, experts broke through the hype to talk about what’s real.

If a group of chemists found 18 more potent versions of a drug out of a sea of 3,000 potential chemicals in the span of a few weeks, they might be hailed as superhumans.

That actually happened at Relay Therapeutics, said Dr. Donald Bergstrom, the company’s head of R&D. But the driving force behind it wasn’t human at all — it was artificial intelligence.

AI and machine learning have been hailed as a powerful new tool for drug discovery. But despite the hype, there is still a huge gap between the potential and the reality.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT1 min read
STAT+: Nuclear Regulatory Commission Advisers Beset By Conflicts Of Interest, Report Finds
Advisers to the Nuclear Regulatory Commission, a U.S. government agency tasked with ensuring the safe use of radioactive materials, were beset by conflicts of interest, report finds

Related Books & Audiobooks